Skip to main content
SpringerLink
Log in

Tourette Syndrome

Clinical Characteristics and Current Management Strategies

  • Review Article
  • Published:
Paediatric Drugs Aims and scope Submit manuscript

Abstract

Tourette Syndrome (TS) is a disorder comprised of involuntary motor and phonic tics often associated with psychiatric conditions. The etiology for TS is unclear, with both genetic and immunological theories being studied to date.

When pharmacotherapy is considered by the patient and physician to be required, owing to either functional impairment from tics or comorbid psychiatric illness, dopamine receptor antagonists are commonly used. Our first-line agents for tic suppression include clonidine, guanfacine, clonazepam and baclofen. Should these agents be ineffective, we would recommend pimozide, fluphenazine, risperidone or haloperidol. The potential benefit of other agents, such as olanzapine, ziprasidone, pergolide and botulinum toxin, is encouraging.

Despite many years of concern, we have found little exacerbation of tics with stimulant medications for attention deficit hyperactivity disorder, but clearly clonidine and guanfacine can ameliorate both comorbid conditions. Obsessive compulsive disorder, when associated with TS, may be treated with either a selective serotonin reuptake inhibitor in association with a dopamine receptor antagonist or risperidone alone. New therapies for all aspects of TS and its comorbid conditions are in active clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gilles de la Tourette G. Etude sur une affection nerveuse caracterisee par de l’incoordination motrice accompagnee d’echolalie et de copralalie. Arch Neurol 1885; 9: 19–42

    Google Scholar 

  2. Gilles de la Tourette G. Etude sur une affection nerveuse caracterisee par de l’incoordination motrice accompagnee d’echolalie et de copralalie. Arch Neurol 1885; 9: 158–200

    Google Scholar 

  3. Itard JMG. Mémoire sur quelques fonctions involontaires des appareils de la locomotion de la préhension et de la voix. Arch Gen Med 1825; 8: 385–407

    Google Scholar 

  4. Burd L, Kergbeshian J, Wikenheiser M, et al. A prevalence study of Gilles de la Tourette syndrome in North Dakota school-age children. J Am Acad Child Psychiatry 1986; 25: 552–3

    Article  PubMed  CAS  Google Scholar 

  5. Hanna PA, Janjua FN, Constant CF, et al. Bilineal transmission in Tourette syndrome. Neurology 1999; 53: 813–8

    Article  PubMed  CAS  Google Scholar 

  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Press, 1995

    Google Scholar 

  7. Feigin A, Clarke H. Tourette syndrome: update and review of the literature. Neurologist 1998; 4: 188–95

    Article  Google Scholar 

  8. Baron-Cohen S, Scahill VL, Izaguirre J, et al. The prevalence of Gilles de la Tourette syndrome in children and adolescents with autism: a large scale study. Psychol Med 1999; 29: 1151–9

    Article  PubMed  CAS  Google Scholar 

  9. Eapen V, Robertson MM, Zeitlin H, et al. Gilles de la Tourette’s syndrome in special education schools: a United Kingdom study. J Neurol 1997; 244: 378–82

    Article  PubMed  CAS  Google Scholar 

  10. Goetz CG, Tanner CM, Stebbins GT, et al. Adult tics in Gilles de la Tourette syndrome. Neurology 1992; 42: 784–8

    Article  PubMed  CAS  Google Scholar 

  11. Leckman JR, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998; 102: 14–9

    Article  PubMed  CAS  Google Scholar 

  12. Erenberg G, Cruse RP, Rothner AD. The natural history of Tourette syndrome: a follow-up study. Ann Neurol 1987; 22: 383–5

    Article  PubMed  CAS  Google Scholar 

  13. Price RA, Kidd KK, Cohen DJ, et al. A twin study of Tourette syndrome. Arch Gen Psychiatry 1985; 42: 815–20

    Article  PubMed  CAS  Google Scholar 

  14. Hyde TM, Aaronson BA, Radolph C, et al. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette’s syndrome. Neurology 1992; 42: 652–8

    Article  PubMed  CAS  Google Scholar 

  15. Walkup JT, LaBuda MC, Singer HS, et al. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996; 59: 684–93

    PubMed  CAS  Google Scholar 

  16. The Tourette Syndrome Association International Consortium for Genetics: a complete genome screen in sib pairs affected by Gilles de la Tourette syndrome. Am J Human Genet 1999; 65: 1428–36

    Google Scholar 

  17. Barr CL, Wigg KG, Pakstis AJ, et al. Genome scan for linkage to Gilles de la Tourette syndrome. Am J Human Genet 1999; 88: 437–45

    CAS  Google Scholar 

  18. Kerbeshian J, Severud R, Burd L, et al. Peek-a-boo fragile site at 16d associated with Tourette syndrome, bipolar disorder, autistic disorder, and mental retardation. Am J Human Genet 2000; 96: 69–73

    CAS  Google Scholar 

  19. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections PANDAS: a clinical description of the first fifty cases. Am J Psychiatry 1998; 155: 264–71

    PubMed  CAS  Google Scholar 

  20. Singer HS, Giuliano JD, Hansen BH, et al. Antibodies against human putamen in children with Tourette syndrome. Neurology 1998; 50: 1618–24

    Article  PubMed  CAS  Google Scholar 

  21. Trifiletti RR, Packard AM. Immune mechanisms in pediatric neuropsychiatric disorders, Tourette’s syndrome, OCD, and PANDAS. Child Adolesc Clin N Am 1999; 8: 767–75

    CAS  Google Scholar 

  22. Hallett JJ, Harling-Berg CJ, Agrawal JR, et al. Tic-like phonation and dyskinesia in rats after intracaudate microinfusion of sera from children with Tourette syndrome [abstract]. FASEB J 1996; 10: A1357

    Google Scholar 

  23. Muller N, Riedel M, Straube A, et al. Increased anti-streptococcal antibodies in patients with Tourette’s syndrome. Psychiatry Res 2000; 94: 43–9

    Article  PubMed  CAS  Google Scholar 

  24. Woods DW, Miltenberger RG, Lumley VA. Sequential application of major habit-reversal components to treat motor tics in children. J Appl Behav Anal 1996; 29: 483–93

    Article  PubMed  CAS  Google Scholar 

  25. Evers RA, van deWetering BJ. A treatment model for motor tics based on a specific tension-reduction technique. J Behav Ther Exp Psychiatry 1994; 25: 255–60

    Article  PubMed  CAS  Google Scholar 

  26. Wright KM, Miltenberger RG. Awareness training in the treatment of head and facial tics. J Behav Ther Exp Psychiatry 1987; 18: 269–74

    Article  PubMed  CAS  Google Scholar 

  27. Bergin A, Waranch HR, Brown J, et al. Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998; 18: 136–42

    Article  PubMed  CAS  Google Scholar 

  28. Chappell PB, Scahill LD, Leckman JF. Future therapies of Tourette syndrome. Neurol Clin N Am 1997; 15: 429–50

    CAS  Google Scholar 

  29. Cohen DJ, Detlor J, Young JG, et al. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37: 1350–7

    Article  PubMed  CAS  Google Scholar 

  30. Arnsten AFT, Contant TA. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology 1992; 108: 159–69

    Article  PubMed  CAS  Google Scholar 

  31. Arnsten AFT, Steere JC, Hunt RD. The contribution of alpha-2 adrenergic mechanisms to prefrontal cortical cognitive function: potential significance to attention deficit disorder. Arch Gen Psychiatry 1996; 53: 448–55

    Article  PubMed  CAS  Google Scholar 

  32. Balldin J, Berggren U, Eriksson E, et al. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion: a comparison with clonidine. Psychoneuroendocrinology 1993; 18: 45–55

    Article  PubMed  CAS  Google Scholar 

  33. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Child Adolesc Psychiatry 1995; 34: 1140–6

    Article  CAS  Google Scholar 

  34. Gonce M, Barbeau A. Seven cases of Gilles de la Tourette’s syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977; 4: 279–83

    PubMed  CAS  Google Scholar 

  35. Steingard RJ, Goldberg M, Lee D, et al. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994; 33: 394–9

    Article  PubMed  CAS  Google Scholar 

  36. Awaad Y. Tics in Tourette syndrome: new treatment options. J Child Neurol 1999; 14: 316–9

    Article  PubMed  CAS  Google Scholar 

  37. Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001; 56: 599–604

    Article  PubMed  CAS  Google Scholar 

  38. Robertson MM. Tourette syndrome: associated conditions and the complexities of treatment. Brain 2000; 123: 425–62

    Article  PubMed  Google Scholar 

  39. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. Am J Psychiatry 1988; 145: 621–4

    PubMed  CAS  Google Scholar 

  40. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette disorder. Am J Psychiatry 1997; 8: 1057–62

    Google Scholar 

  41. Van der Linden C, Bruggeman R, Van Woerkom T. Serotonin-dopamine antagonist and Gilles de la Tourette’s syndrome: an open pilot dose-titration study with risperidone [letter]. Mov Disord 1994; 9: 687–8

    Article  PubMed  Google Scholar 

  42. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34: 1147–52

    Article  PubMed  CAS  Google Scholar 

  43. Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry 1996; 57: 29–31

    PubMed  CAS  Google Scholar 

  44. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136: 317–20

    PubMed  CAS  Google Scholar 

  45. Jaffe E, Tremeau F, Sharif Z, et al. Clozapine in tardive Tourette syndrome. Biol Psychiatry 1995; 38: 196–7

    Article  PubMed  CAS  Google Scholar 

  46. Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenzine. J Nerv Ment Dis 1993; 181: 649–51

    Article  PubMed  CAS  Google Scholar 

  47. Benji Semerci Z. Olanzapine in Tourette’s disorder [letter]. J Am Acad Child Adolesc Psychiatry 2000; 39: 140

    Article  Google Scholar 

  48. Karam-Hage M, Ghaziuddin N. Olanzapine in Tourette’s disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 140

    Article  Google Scholar 

  49. Stamenkovic M, Schnidler SD, Aschauer HN, et al. Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin Psychopharmocol 2000; 15: 23–8

    Article  CAS  Google Scholar 

  50. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39: 292–9

    Article  PubMed  CAS  Google Scholar 

  51. Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47: 1010–32

    Article  PubMed  CAS  Google Scholar 

  52. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988; 237: 223–9

    Article  PubMed  CAS  Google Scholar 

  53. Black KJ, Mink JW. Response to levodopa challenge in Tourette syndrome. Mov Disord 2000; 15: 1194–8

    Article  PubMed  CAS  Google Scholar 

  54. Gilbert DL, Sethuraman G, Sine L, et al. Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000; 54: 1310–5

    Article  PubMed  CAS  Google Scholar 

  55. Lipinski JF, Sallee FR, Jackson C, et al. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997; 12: 402–7

    Article  PubMed  CAS  Google Scholar 

  56. Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette’s syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 1994; 9: 315–7

    Article  PubMed  CAS  Google Scholar 

  57. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics and other hyperkinesias. Neurology 1988; 38: 391–4

    Article  PubMed  CAS  Google Scholar 

  58. Peterson BS, Zhang H, Anderson GM, et al. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998; 18: 324–31

    Article  PubMed  CAS  Google Scholar 

  59. Muller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: possible role in pathophysiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 1998; 98: 502–6

    Article  PubMed  CAS  Google Scholar 

  60. Muller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannibinol [letter]. Am J Psychiatry 1999; 156: 495

    PubMed  CAS  Google Scholar 

  61. Dursun SM, Reveley MA. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette’s syndrome: an open study. Psychol Med 1997; 27: 483–7

    Article  PubMed  CAS  Google Scholar 

  62. Sanberg PR, McConville BJ, Fogelson HM, et al. Nicotine potentiates the effects of haloperidol in animals and patients with Tourette syndrome. Biomed Pharmacother 1989; 43:19–23

    Article  PubMed  CAS  Google Scholar 

  63. Sanberg PR, Silver AA, Shytle RD, et al. Nicotine for the treatment of Tourette’s syndrome. Pharmacol Ther 1997; 74: 21–5

    Article  PubMed  CAS  Google Scholar 

  64. Sanberg PR, Shytle RD, Silver AA. Treatment of Tourette’s syndrome with mecamylamine. Lancet 1998; 352: 705–6

    Article  PubMed  CAS  Google Scholar 

  65. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994; 9: 347–9

    Article  PubMed  CAS  Google Scholar 

  66. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000; 57: 1190–3

    Article  PubMed  CAS  Google Scholar 

  67. Cath DC, Gijsman HJ, Schoemaker RC, et al. The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology 1999; 144: 137–43

    Article  PubMed  CAS  Google Scholar 

  68. Toren P, Laor N, Cohen DJ, et al. Ondansetron treatment in patients with Tourette’s syndrome. Int Clin Psychopharmacol 1999; 14: 373–6

    Article  PubMed  CAS  Google Scholar 

  69. Scahill L, Riddle MA, King RA, et. al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997; 7: 75–85

    Article  PubMed  CAS  Google Scholar 

  70. Bajo S, Battaglia M, Pegna C, et al. Citalopram and fluvoxamine in Tourette’s disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 230–1

    Article  PubMed  CAS  Google Scholar 

  71. Pollack MA, Cohen NL, Friedhoff AJ. Gilles de la Tourette’s syndrome: familial occurrence and precipitation by methyl-phenidate therapy. Arch Neurol 1977; 34: 630–2

    Article  PubMed  CAS  Google Scholar 

  72. Golden GS. The effect of central nervous system stimulants on Tourette syndrome. Ann Neurol 1977; 2: 69–70

    Article  PubMed  CAS  Google Scholar 

  73. Lowe TL, Cohen DJ, Detlor J, et al Stimulant medications precipitate Tourette’s syndrome. JAMA 1982; 247: 1729–31

    Article  PubMed  CAS  Google Scholar 

  74. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999; 38: 944–51

    Article  PubMed  CAS  Google Scholar 

  75. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyper-activity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999; 56: 330–6

    Article  PubMed  CAS  Google Scholar 

  76. Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawn during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999; 103: 730–7

    Article  PubMed  CAS  Google Scholar 

  77. Feigin A, Kurlan R, McDermott MP, et al. A controlled trial of deprenyl in children with Tourette’s syndrome and attention-deficit hyperactivity disorder. Neurology 1996; 46: 965–8

    Article  PubMed  CAS  Google Scholar 

  78. Giakas WJ. Risperidone treatment for a Tourette’s disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 1097–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Paediatrics and Neurology, Pathology 509, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, Maryland, 21287, USA

    Eric H. Kossoff & Harvey S. Singer

Authors
  1. Eric H. Kossoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harvey S. Singer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric H. Kossoff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kossoff, E.H., Singer, H.S. Tourette Syndrome. Paediatr Drugs 3, 355–363 (2001). https://doi.org/10.2165/00128072-200103050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200103050-00004

Keywords

Search

Navigation